141 related articles for article (PubMed ID: 9592185)
21. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins.
Salcini AE; McGlade J; Pelicci G; Nicoletti I; Pawson T; Pelicci PG
Oncogene; 1994 Oct; 9(10):2827-36. PubMed ID: 8084588
[TBL] [Abstract][Full Text] [Related]
22. Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection.
Mahlmann S; McLaughlin J; Afar DE; Mohr R; Kay RJ; Witte ON
Leukemia; 1998 Dec; 12(12):1858-65. PubMed ID: 9844916
[TBL] [Abstract][Full Text] [Related]
23. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.
Goga A; McLaughlin J; Afar DE; Saffran DC; Witte ON
Cell; 1995 Sep; 82(6):981-8. PubMed ID: 7553858
[TBL] [Abstract][Full Text] [Related]
24. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
25. Bcr phosphorylated on tyrosine 177 binds Grb2.
Ma G; Lu D; Wu Y; Liu J; Arlinghaus RB
Oncogene; 1997 May; 14(19):2367-72. PubMed ID: 9178913
[TBL] [Abstract][Full Text] [Related]
26. Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc.
Liu L; Damen JE; Cutler RL; Krystal G
Mol Cell Biol; 1994 Oct; 14(10):6926-35. PubMed ID: 7523859
[TBL] [Abstract][Full Text] [Related]
27. Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells.
Sakaguchi K; Okabayashi Y; Kido Y; Kimura S; Matsumura Y; Inushima K; Kasuga M
Mol Endocrinol; 1998 Apr; 12(4):536-43. PubMed ID: 9544989
[TBL] [Abstract][Full Text] [Related]
28. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells.
Zhang S; Mantel C; Broxmeyer HE
J Leukoc Biol; 1999 Mar; 65(3):372-80. PubMed ID: 10080542
[TBL] [Abstract][Full Text] [Related]
29. Differential complementation of Bcr-Abl point mutants with c-Myc.
Afar DE; Goga A; McLaughlin J; Witte ON; Sawyers CL
Science; 1994 Apr; 264(5157):424-6. PubMed ID: 8153630
[TBL] [Abstract][Full Text] [Related]
30. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
Ilaria RL; Van Etten RA
Blood; 1995 Nov; 86(10):3897-904. PubMed ID: 7579359
[TBL] [Abstract][Full Text] [Related]
31. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
32. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
[TBL] [Abstract][Full Text] [Related]
33. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
Zhang X; Subrahmanyam R; Wong R; Gross AW; Ren R
Mol Cell Biol; 2001 Feb; 21(3):840-53. PubMed ID: 11154271
[TBL] [Abstract][Full Text] [Related]
34. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
[TBL] [Abstract][Full Text] [Related]
35. Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence.
Maru Y; Witte ON; Shibuya M
FEBS Lett; 1996 Feb; 379(3):244-6. PubMed ID: 8603698
[TBL] [Abstract][Full Text] [Related]
36. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.
Sattler M; Salgia R
Leukemia; 1998 May; 12(5):637-44. PubMed ID: 9593259
[TBL] [Abstract][Full Text] [Related]
37. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
Heaney C; Kolibaba K; Bhat A; Oda T; Ohno S; Fanning S; Druker BJ
Blood; 1997 Jan; 89(1):297-306. PubMed ID: 8978305
[TBL] [Abstract][Full Text] [Related]
38. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
Million RP; Van Etten RA
Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
[TBL] [Abstract][Full Text] [Related]
39. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.
Sattler M; Verma S; Pride YB; Salgia R; Rohrschneider LR; Griffin JD
J Biol Chem; 2001 Jan; 276(4):2451-8. PubMed ID: 11031258
[TBL] [Abstract][Full Text] [Related]
40. B cell antigen receptor cross-linking induces tyrosine phosphorylation and membrane translocation of a multimeric Shc complex that is augmented by CD19 co-ligation.
Lankester AC; van Schijndel GM; Rood PM; Verhoeven AJ; van Lier RA
Eur J Immunol; 1994 Nov; 24(11):2818-25. PubMed ID: 7525306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
